A New Era for Cystic Fibrosis and Cystic Fibrosis Transmembrane Conductance Regulator Modulator Trials in Infants

Affiliations

Editorial

Claire E Wainwright. Am J Respir Crit Care Med. 2022.

. 2022 Nov 15;206(10):1193-1195.

doi: 10.1164/rccm.202207-1356ED.

¹ Paediatrics and Child Health University of Queensland South Brisbane, Queensland, Australia.

No abstract available

Comment on

A Phase 3, Open-Label Study of Lumacaftor/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for F508del-CFTR.
Rayment JH, Asfour F, Rosenfeld M, Higgins M, Liu L, Mascia M, Paz-Diaz H, Tian S, Zahigian R, McColley SA. Rayment JH, et al. Am J Respir Crit Care Med. 2022 Nov 15;206(10):1239-1247. doi: 10.1164/rccm.202204-0734OC. Am J Respir Crit Care Med. 2022. PMID: 35771568 Free PMC article. Clinical Trial.

1. Lopes-Pacheco M. CFTR Modulators: the changing face of cystic fibrosis in the era of precision medicine. Front Pharmacol . 2020;10:1662. - PMC - PubMed
1. Bessonova L, Volkova N, Higgins M, Bengtsson L, Tian S, Simard C, et al. Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor. Thorax . 2018;73:731–740. - PMC - PubMed
1. De Boeck K. Cystic fibrosis in the year 2020: a disease with a new face. Acta Paediatr . 2020;109:893–899. - PubMed
1. O’Sullivan BP, Baker D, Leung KG, Reed G, Baker SS, Borowitz D. Evolution of pancreatic function during the first year in infants with cystic fibrosis. J Pediatr . 2013;162:808–812.e1. - PubMed
1. Fayon M, Ladipo Y, Galode F, Debelleix S, Reix P. 2016;23:12S9–12S14. - PubMed